SPAC-on-SPAC Deal Falls Apart, and So Does Immunovant’s Stock

(Bloomberg) — A private drugmaker aborted plans to buy back its own SPAC at a hefty premium, sending shares of Immunovant Inc. plunging to an all-time low.The withdrawal by Roivant Sciences Ltd. unwinds part of its plan to go public by selling itself to a special-purpose acquisition company, and then using the proceeds to reacquire full ownership of Immunovant, which it merged into another SPAC in 2019. Immunovant’s stock, which topped $53 last year, closed 26% lower. Instead, Roivant said in a

(Excerpt) Read more Here | 2021-08-02 14:05:52
Image credit: source


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.